Floatz logo

Letrozole

Hereditary Breast/Ovarian Cancer (brca1, brca2)

UNICANCERSmall moleculePhase 3Dormant
BB
64/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
49/ 100
Competitive Position
95/ 100

Competitive context

1 Active assets in the Hereditary Breast/Ovarian Cancer (brca1, brca2) cohort.

Asset / SponsorPhaseRating
TAMOXIFEN
The Cleveland Clinic
Phase 2B
Arzoxifene
The Cleveland Clinic
Phase 2B
Docetaxel
University College London Hospitals
Phase 2B
PANITUMUMAB
Beaumont Hospital
N/AD

Same molecule, other indications

Letrozole is also rated in:

infertility disorderDormant
BBB
Indicative ·
79 / 100
View asset →
anovulationDormant
BBB
Indicative ·
78 / 100
View asset →
Diabetes MellitusDormant
BBB
Indicative ·
77 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →